AYTU BIOPHARMA, INC
AYTUNasdaq
$2.15
↓ -0.5%Jul 17 close · end-of-day
Price
1Y↓ -7.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$22.6M
Enterprise Value
$7.3M
P/E
—
P/S
0.4
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
7.3%
Dividend Yield
—
Revenue (TTM)
$56.6M
Net Income (TTM)
-$34.1M
Free Cash Flow (TTM)
$1.6M
Gross Margin
64.8%
Operating Margin
-26.8%
Net Margin
-60.2%
ROE
-96.9%
ROIC
-60.4%
Debt / Equity
0.3
Net Cash
$15.3M
Return 1Y
-9.7%
Company profile
Aytu Biopharma, Inc. focuses on developing and commercializing novel therapeutics and consumer healthcare products. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the. treatment of seasonal and perennial allergies.
- CEO
- Joshua R. Disbrow
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 160
- Headquarters
- Colorado
- Website
- aytubio.com
Management & directors
- Disbrow JarrettChief Business Officer
- Disbrow Joshua R.Chief Executive Officer
- Pyszczymuka GregChief Commercial Officer
- Selhorn Ryan JChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
AYTU Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$12.4M↓ -32.7%
Diluted EPS-$0.53↓ -352.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $65.6M | $96.7M | $107.4M | $65.2M | $66.4M |
| Gross profit | $29.2M | $52.3M | $66.6M | $49.1M | $45.8M |
| Operating income | -$58.9M | -$109.9M | -$17.1M | -$1.6M | -$7.8M |
| Net income | -$58.3M | -$108.8M | -$17.1M | -$15.8M | -$13.6M |
| Diluted EPS | -$3.48 | -$74.01 | -$5.11 | — | — |
| Operating cash flow | -$26.0M | -$28.8M | -$5.1M | -$1.4M | -$1.9M |
| Free cash flow | — | — | — | -$1.7M | -$2.2M |
| Gross margin | 44.5% | 54.1% | 62.0% | 75.3% | 69.0% |
| Operating margin | -89.7% | -113.7% | -15.9% | -2.4% | -11.8% |
| Net margin | -88.8% | -112.5% | -15.9% | -24.3% | -20.4% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $16.6M | $16.2M | $18.5M | $15.1M | $13.9M | $15.2M | $12.4M |
| Gross profit | $11.1M | $12.0M | $10.8M | $12.8M | $10.3M | $9.2M | $9.6M | $7.6M |
| Operating income | -$2.3M | -$930,000.00 | -$1.7M | $2.4M | -$7.6M | -$1.5M | -$2.0M | -$4.1M |
| Net income | -$4.6M | $1.5M | $788,000.00 | $4.0M | -$19.8M | $2.0M | -$10.6M | -$5.6M |
| Diluted EPS | — | -$0.15 | -$0.26 | $0.21 | — | -$0.08 | -$1.05 | -$0.53 |
| Operating cash flow | -$788,000.00 | -$1.2M | $2.9M | -$6.5M | $2.8M | -$618,000.00 | $3.7M | -$4.2M |
| Free cash flow | — | -$1.3M | $2.9M | -$6.5M | $2.8M | -$618,000.00 | $3.7M | -$4.2M |
| Gross margin | 75.7% | 72.3% | 66.5% | 69.4% | 67.8% | 66.1% | 63.5% | 61.2% |
| Operating margin | -15.6% | -5.6% | -10.4% | 13.1% | -50.4% | -10.8% | -13.0% | -32.7% |
| Net margin | -31.6% | 8.9% | 4.9% | 21.6% | -130.9% | 14.1% | -69.8% | -45.3% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-03 | PYSZCZYMUKA GREG· Chief Commercial Officer | Award | 12,500 | $0.00 | $0.00 | filing |
| 2025-10-03 | Disbrow Jarrett· Chief Business Officer | Award | 19,606 | $0.00 | $0.00 | filing |
| 2025-10-03 | Disbrow Jarrett· Chief Business Officer | Award | 12,500 | $0.00 | $0.00 | filing |
| 2025-10-03 | Selhorn Ryan J· Chief Financial Officer | Award | 16,243 | $0.00 | $0.00 | filing |
| 2025-10-03 | Selhorn Ryan J· Chief Financial Officer | Award | 17,500 | $0.00 | $0.00 | filing |
| 2025-10-03 | Disbrow Joshua R.· Chief Executive Officer | Award | 31,446 | $0.00 | $0.00 | filing |
| 2025-10-03 | Disbrow Joshua R.· Chief Executive Officer | Award | 22,500 | $0.00 | $0.00 | filing |
| 2025-10-03 | LIU VIVIAN H | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-10-03 | JAIN ABHINAV | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-10-03 | DOCKERY CARL | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-10-03 | Donofrio John Jr. | Award | 10,000 | $0.00 | $0.00 | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.